Inicio › Cáncer de seno › Tennessee
Ensayos clínicos de Cáncer de seno en Tennessee
91 estudios sobre Cáncer de seno buscan participantes en Tennessee.
Ciudades en Tennessee
Texto oficial del estudio (inglés)
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
- The West Cancer Center, Memphis
- SCRI Oncology Partners, Nashville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT07701941Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Sarah Cannon Research Institute, Nashville
ReclutandoFase 3
Edades de 18 a 100 · Todos los sexos · Actualizado el 1 oct 2026 · NCT05827081A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- Sarah Cannon Research Institute (Nashville), Nashville
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT07102381A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Tennessee Oncology, Greco-Hainsworth Center for Research, Nashville
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06369285Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06625775A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- SCRI Oncology Partners, Nashville
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06172478Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Baptist Cancer Center - Memphis, Memphis
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Pllc, Nashville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT06324357A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Nashville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT05877599IKS014 in Advanced Solid Tumors That Express HER2
- Tennessee Oncology, Nashville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT05872295A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- SCRI Oncology Partners ( Site 7000), Nashville
- Tennessee Oncology ( Site 0068), Nashville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07060807BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Scri Oncology Partners, Nashville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT06120283A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Chattanooga
- Research Site, Nashville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06103864A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Tennessee Cancer Specialists ( Site 7001), Knoxville
- SCRI Oncology Partners ( Site 7005), Nashville
- Nashville General Hospital ( Site 0017), Nashville
- y 1 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06966700The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Baptist Memorial Healthcare, Memphis
ReclutandoFase 3
Edades de 60 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06377852A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
- West Cancer Center, Germantown
ReclutandoFase 2
Edades de 18 en adelante · Mujeres · Actualizado el 25 sept 2026 · NCT07054190Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- Vanderbilt Ingram Cancer Center, Nashville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT05523947Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Bartlett
- Clinical Trial Site, Knoxville
- Clinical Trial Site, Mount Juliet
- y 2 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- West Cancer Center, Germantown
- Vanderbilt, Nashville
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT07214532A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- University of Tennessee Medical Center, Knoxville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT06618287A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Sarah Cannon Research Institute SCRI, Nashville
- Nashville General Hospital, Nashville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07174336A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Tennessee Oncology, Nashville
ReclutandoFase 2
Edades de 18 en adelante · Mujeres · Actualizado el 22 sept 2026 · NCT07287098A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
- SCRI Oncology Partners, Nashville
ReclutandoFase 1
Edades de 18 en adelante · Mujeres · Actualizado el 21 sept 2026 · NCT07524855A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Sarah Cannon Nashville, Nashville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT07109726A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- SCRI Oncology Partners, Nashville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT06827236ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- The West Clinic, P.C. dba West Cancer Center, Germantown
- Tennessee Oncology, Nashville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT07173751The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Sarah Cannon Research Institute, Nashville
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT04585750A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Baptist Cancer Center, Memphis
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC, Nashville
- y 1 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT06492616Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- SCRI Oncology Partners ( Site 7000), Nashville
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 sept 2026 · NCT06797635A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Tennessee Oncology - Chattanooga Oncology & Hematology Associates, Chattanooga
- The West Clinic, Germantown
- Tennessee Oncology PLLC, Nashville
- y 1 más
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 sept 2026 · NCT03424005Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Sarah Cannon Research Institute, Nashville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 sept 2026 · NCT06293898A Phase 1/1b Study of IAM1363 in HER2 Cancers
- SCRI Oncology Partners, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 sept 2026 · NCT06253871Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)
- The West Clinic, PC dba West Cancer Center, Germantown
Reclutando
Edades de 70 en adelante · Todos los sexos · Actualizado el 9 sept 2026 · NCT07629206Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- SCRI Oncology Partners, Nashville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 sept 2026 · NCT05386108A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Center, Nashville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 sept 2026 · NCT06440005A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT07100106A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Nashville
ReclutandoFase 3
Edades de 18 a 130 · Todos los sexos · Actualizado el 8 sept 2026 · NCT07647328Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- Sarah Cannon Research Institute Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Institute, Nashville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT07287917A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- West Cancer Center, Germantown
- Vanderbilt University Medical Center, Nashville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT06790693Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Nashville General, Nashville
ReclutandoEstudio observacional
Edades de 18 a 99 · Todos los sexos · Actualizado el 3 sept 2026 · NCT07211178A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- SCRI Oncology Partners, Nashville
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT06760819De ClinicalTrials.gov, datos obtenidos el 2 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.